38,465 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,465 shares of the company’s stock, valued at approximately $752,000.

Several other large investors have also bought and sold shares of VRDN. Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its position in shares of Viridian Therapeutics by 10.8% in the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 69,530 shares of the company’s stock valued at $1,360,000 after buying an additional 6,801 shares during the last quarter. Strs Ohio bought a new position in shares of Viridian Therapeutics during the first quarter worth about $417,000. SG Americas Securities LLC lifted its stake in shares of Viridian Therapeutics by 81.5% in the first quarter. SG Americas Securities LLC now owns 60,044 shares of the company’s stock worth $1,174,000 after acquiring an additional 26,956 shares during the period. Avoro Capital Advisors LLC acquired a new position in shares of Viridian Therapeutics in the fourth quarter worth approximately $46,680,000. Finally, Seven Fleet Capital Management LP bought a new stake in Viridian Therapeutics in the fourth quarter valued at approximately $456,000.

Insider Activity

In related news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is owned by insiders.

Viridian Therapeutics Trading Down 5.4%

NASDAQ VRDN opened at $18.03 on Friday. The stock has a market capitalization of $1.86 billion, a P/E ratio of -5.43 and a beta of 0.90. The business has a 50 day simple moving average of $17.47 and a 200 day simple moving average of $22.91. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. Viridian Therapeutics, Inc. has a one year low of $13.18 and a one year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company’s revenue was up 95.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.87) earnings per share. Research analysts expect that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Wall Street Analyst Weigh In

VRDN has been the subject of a number of recent analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $39.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Evercore set a $26.00 price objective on shares of Viridian Therapeutics in a research note on Friday, May 15th. Royal Bank Of Canada increased their price objective on shares of Viridian Therapeutics from $34.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. HC Wainwright lowered their target price on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Wells Fargo & Company upgraded shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $20.00 to $31.00 in a report on Monday, June 29th. Thirteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.79.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.